PHAXIAM Therapeutics (XPAR:PHXM) OCF Margin %: 0.00% (As of Sep. 2023)


XPAR:PHXM PHAXIAM Therapeutics SA XPAR:PHXM
38 GF Score
Price €0.10
View Full Analysis

What is PHAXIAM Therapeutics OCF Margin %?

PHAXIAM Therapeutics XPAR:PHXM 38 OCF Margin % is 0.00% as of Sep. 2023. GuruFocus rates XPAR:PHXM with a GF Score™ of 38/100.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. PHAXIAM Therapeutics's Cash Flow from Operations for the three months ended in Sep. 2023 was €0.00 Mil. PHAXIAM Therapeutics's Revenue for the three months ended in Sep. 2023 was €0.00 Mil. Therefore, PHAXIAM Therapeutics's OCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

As of today, PHAXIAM Therapeutics's current OCF Yield % is 0.00%.

The historical rank and industry rank for PHAXIAM Therapeutics's OCF Margin % or its related term are showing as below:


XPAR:PHXM's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

PHAXIAM Therapeutics OCF Margin % Related Terms

PHAXIAM Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics OCF Margin % Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:PHXM
38GF Score
PHAXIAM Therapeutics SA XPAR:PHXM
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

PHAXIAM Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-31.764/0
= %

PHAXIAM Therapeutics's OCF Margin for the quarter that ended in Sep. 2023 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
PHAXIAM Therapeutics (XPAR:PHXM) has a OCF Margin % of 0.00% as of Sep. 2023. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' OCF Margin % too high?
PHAXIAM Therapeutics' current OCF Margin % is 0.00%. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' OCF Margin % compare to VRTX and REGN?
PHAXIAM Therapeutics' OCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (XPAR:PHXM) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For PHAXIAM Therapeutics (XPAR:PHXM), the current OCF Margin % is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for XPAR:PHXM

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price